Minami Kouichiro, Uezono Yasuhito, Ueta Yoichi
Department of Anesthesiology and Critical Care Medicine, Jichi Medical University, Japan.
J Pharmacol Sci. 2007 Mar;103(3):253-60. doi: 10.1254/jphs.cr0060032.
Tramadol is an analgesic that is used worldwide, but its mechanisms of action have not been elucidated. It has been speculated that tramadol acts primarily through the activation of micro-opioid receptors and the inhibition of monoamine reuptake. The majority of studies to date have focused on ion channels in the central nervous system as targets of anesthetics and analgesics. During the past decade, major advances have been made in our understanding of the physiology and pharmacology of G-protein coupled receptor (GPCR) signaling. Several studies have shown that GPCRs and ion channels are targets for analgesics and anesthetics. In particular, tramadol has been shown to affect GPCRs, including muscarinic acetylcholine receptors and 5-hydroxytryptamine receptors. Here, the effects of tramadol on monoamine transporters, GPCRs, and ion channels are presented, and recent research on the pharmacology of tramadol is discussed.
曲马多是一种在全球范围内使用的镇痛药,但其作用机制尚未阐明。据推测,曲马多主要通过激活微阿片受体和抑制单胺再摄取发挥作用。迄今为止,大多数研究都集中在中枢神经系统中的离子通道作为麻醉药和镇痛药的靶点。在过去十年中,我们对G蛋白偶联受体(GPCR)信号传导的生理学和药理学的理解取得了重大进展。几项研究表明,GPCR和离子通道是镇痛药和麻醉药的靶点。特别是,曲马多已被证明会影响GPCR,包括毒蕈碱型乙酰胆碱受体和5-羟色胺受体。在此,介绍了曲马多对单胺转运体、GPCR和离子通道的影响,并讨论了曲马多药理学的最新研究。